Successful salvage treatment of resistant acute antibody-mediated kidney transplant rejection with eculizumab

Saif A. Khan*, Dawood Al-Riyami, Yasser W. Al-Mula Abed, Saja Mohammed, Marwa Al-Riyami, Nabil M. Al-Lawati

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


Antibody-mediated rejection (ABMR) jeopardises short- and long-term transplant survival and remains a challenge in the field of organ transplantation. We report the first use of the anticomplement agent eculizumab in Oman in the treatment of a 61-year-old female patient with ABMR following a living unrelated kidney transplant. The patient was admitted to the Sultan Qaboos University Hospital in Muscat, Oman, in 2013 on the eighth day post-transplantation with serum creatinine (Cr) levels of 400 µmol/L which continued to rise, necessitating haemodialysis. A biopsy indicated ABMR with acute cellular rejection. No improvement was observed following standard ABMR treatment and she continued to require dialysis. Five doses of eculizumab were administered over six weeks with a subsequent dramatic improvement in renal function. The patient became dialysis-free with serum Cr levels of 119 µmol/L within four months. This case report indicates that eculizumab is a promising agent in the treatment of ABMR.

Original languageEnglish
Pages (from-to)e371-e374
JournalSultan Qaboos University Medical Journal
Issue number3
Publication statusPublished - Aug 2016


  • Case report
  • Complement activation
  • Eculizumab
  • Kidney transplantation
  • Oman
  • Transplantation rejection

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Successful salvage treatment of resistant acute antibody-mediated kidney transplant rejection with eculizumab'. Together they form a unique fingerprint.

Cite this